GlassScriptPhysician profile
Brad H Kimura
NPI 1225425606
$2,259.28
in general payments reported to CMS, 2019-2025
10 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2021: $281 · 2022: $642 · 2023: $61.61 · 2024: $178 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $915.19 | 2021-2025 | |
| Pfizer INC. | $750.00 | 2019 | |
| Novo Nordisk INC | $287.63 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $103.97 | 2021-2022 | |
| Glaxosmithkline, LLC. | $68.70 | 2022 | |
| Lilly USA, LLC | $52.37 | 2022 | |
| Abbott Laboratories | $24.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.43 | 2022 | |
| Tandem Diabetes Care, INC. | $19.45 | 2022 | |
| Zealand Pharma US, INC. | $16.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Kimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.